{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T07:47:24Z","timestamp":1794210444569,"version":"4.8.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1097\/gme.0b013e31826d36ba","type":"journal-article","created":{"date-parts":[[2012,10,26]],"date-time":"2012-10-26T07:13:35Z","timestamp":1351235615000},"page":"418-427","source":"Crossref","is-referenced-by-count":112,"title":["One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus"],"prefix":"10.1097","volume":"20","author":[{"given":"James A.","family":"Simon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian H.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Radovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria A.","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210211","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4065\/mcp.2009.0413","article-title":"Vulvovaginal atrophy.","volume":"85","author":"Mac Bride","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"R2-10-20210211","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/13697130802585576","article-title":"Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview.","volume":"12","author":"Al-Baghdadi","year":"2009","journal-title":"Climacteric"},{"key":"R3-10-20210211","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1111\/j.1743-6109.2009.01335.x","article-title":"Prevalence and impact of vaginal symptoms among postmenopausal women.","volume":"6","author":"Santoro","year":"2009","journal-title":"J Sex Med"},{"key":"R4-10-20210211","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.maturitas.2004.06.019","article-title":"Self-reported urogenital symptoms in postmenopausal women: Womens Health Initiative.","volume":"49","author":"Pastore","year":"2004","journal-title":"Maturitas"},{"key":"R7-10-20210211","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/gme.0b013e31815a5168","article-title":"Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women.","volume":"15","author":"Levine","year":"2008","journal-title":"Menopause"},{"key":"R8-10-20210211","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/gme.0b013e318051718c","article-title":"The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society.","volume":"14","year":"2007","journal-title":"Menopause"},{"key":"R9-10-20210211","first-page":"1107","article-title":"Vulvovaginal atrophy (VVA) negatively impacts sexual function, psychosocial well-being, and partner relationships. Presented at: 18th Annual Meeting of The North American Menopause Society; October 3-6, 2007; Dallas, TX. LB-10.","volume":"14","author":"Simon","year":"2007","journal-title":"Menopause"},{"key":"R11-10-20210211","first-page":"S14","article-title":"Impact of vaginal atrophy on quality of life and sexuality.","volume":"22","author":"Krychman","year":"2010","journal-title":"OBG Manag"},{"key":"R12-10-20210211","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1001\/jama.281.23.2173","article-title":"Survey says patients expect little physician help on sex.","volume":"281","author":"Marwick","year":"1999","journal-title":"JAMA"},{"key":"R14-10-20210211","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/j.1743-6109.2009.01692.x","article-title":"Vulvovaginal atrophy: current and future therapies (CME).","volume":"7","author":"Ibe","year":"2010","journal-title":"J Sex Med"},{"key":"R20-10-20210211","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1210\/endo.141.2.7342","article-title":"Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats.","volume":"141","author":"Qu","year":"2000","journal-title":"Endocrinology"},{"key":"R21-10-20210211","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0960-0760(01)00066-8","article-title":"In vitro and in vivo biologic effects of ospemifene (FC-1271a) in breast cancer.","volume":"77","author":"Taras","year":"2001","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R22-10-20210211","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/gme.0b013e3181c1ac01","article-title":"Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study.","volume":"17","author":"Bachmann","year":"2010","journal-title":"Menopause"},{"key":"R23-10-20210211","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/01.GME.0000063609.62485.27","article-title":"Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial.","volume":"10","author":"Rutanen","year":"2003","journal-title":"Menopause"},{"key":"R27-10-20210211","first-page":"1252","article-title":"Long-term effects of ospemifene on the clinical signs of vaginal atrophy. Presented at: 20th Annual Meeting of The North American Menopause Society; September 30-October 3, 2009; San Diego, CA. P-42.","volume":"16","author":"Portman","year":"2009","journal-title":"Menopause"},{"key":"R28-10-20210211","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Womens Health Initiative randomized controlled trial.","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"R29-10-20210211","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/0002-9378(79)90289-8","article-title":"Effects of long-term estrogen replacement therapy, II: neoplasia.","volume":"133","author":"Hammond","year":"1979","journal-title":"Am J Obstet Gynecol"},{"key":"R30-10-20210211","first-page":"CD000402","article-title":"Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding.","volume":"3","author":"Lethaby","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"R31-10-20210211","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1056\/NEJM197512042932302","article-title":"Association of exogenous estrogen and endometrial carcinoma.","volume":"293","author":"Smith","year":"1975","journal-title":"N Engl J Med"},{"key":"R32-10-20210211","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/gme.0b013e3181c4f1d6","article-title":"Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.","volume":"17","author":"Pinkerton","year":"2010","journal-title":"Menopause"},{"key":"R33-10-20210211","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/sti.74.1.11","article-title":"Influence of ovarian hormones on urogenital infection.","volume":"74","author":"Sonnex","year":"1998","journal-title":"Sex Transm Infect"},{"key":"R34-10-20210211","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/01.GME.0000063566.84134.98","article-title":"Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women.","volume":"10","author":"Ylikorkala","year":"2003","journal-title":"Menopause"},{"key":"R35-10-20210211","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/gme.0b013e3181c617e6","article-title":"Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society.","volume":"17","year":"2010","journal-title":"Menopause"},{"key":"R36-10-20210211","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1471-2261-6-40","article-title":"Estrogens, selective estrogen receptor modulators, and a selective estrogen receptor down-regulator inhibit endothelial production of tissue factor pathway inhibitor 1.","volume":"6","author":"Dahm","year":"2006","journal-title":"BMC Cardiovasc Disord"}],"container-title":["Menopause"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00042192-201304000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T15:54:59Z","timestamp":1646236499000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042192-201304000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/gme.0b013e31826d36ba","relation":{},"ISSN":["1072-3714"],"issn-type":[{"value":"1072-3714","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}